Unity Biotechnology Company
Clinical-stage biotech established in 2011 in South San Francisco. Unity develops drugs that target cellular senescence, aiming to slow, halt, or reverse diseases of aging. Its pipeline includes ophthalmologic diseases (e.g., diabetic macular edema), musculoskeletal disorders, and neurodegenerative conditions. Unity was one of the first public companies explicitly branded around “senolytics.” (unitybiotechnology.com)
Investors
Connections from
Headquarters:
285 E Grand Ave, South San Francisco, CA 94080, US
Employee Number:
30
Estimated Revenue:
No public info
Founded Date:
2011